Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here

Keith Lance Investment Overview I last covered Tandem Diabetes Care (NASDAQ:TNDM) in a note for Seeking Alpha back in November 2020, when the automated insulin pump solutions provider's stock price traded at ~$115. I gave the stock a "Buy" recommendation, which initially proved to be the right call, as 12 months on, it had reached a high of$150 per share. In 2020, Tandem delivered revenues of $499m, and an operating loss of$(8m). In 2021, revenues grew to $703m, and a small operating profit of$23m was ac ...